Clovis Oncology Inc
Change company Symbol lookup
Select an option...
CLVS Clovis Oncology Inc
IMLFF InMed Pharmaceuticals Inc
PNW Pinnacle West Capital Corp
AAPL Apple Inc
NAII Natural Alternatives International Inc
SJMiv.P Invesco BulletShares 2022 Hi Yld Corp Bd ETF
INTC Intel Corp
VAL Valaris PLC
GE General Electric Co
XOM Exxon Mobil Corp
Go

Health Care : Biotechnology | Small Cap GrowthCompany profile

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).

Closing Price
$10.71
Day's Change
1.10 (11.45%)
Bid
--
Ask
--
B/A Size
--
Day's High
10.87
Day's Low
9.70
Volume
(Light)
Volume:
14,076,771

10-day average volume:
22,065,488
14,076,771

Display:

Providers:

UpdateCancel
7 providers
December 02, 2019
November 26, 2019
November 13, 2019
November 07, 2019
October 29, 2019
October 22, 2019
October 11, 2019
September 29, 2019
September 23, 2019
September 12, 2019

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.